416 related articles for article (PubMed ID: 15769620)
1. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system.
Maurice DH
Front Biosci; 2005 May; 10():1221-8. PubMed ID: 15769620
[TBL] [Abstract][Full Text] [Related]
2. Changes in phosphodiesterase activity in the developing rat submandibular gland.
Tanaka S; Shimooka S; Shimomura H
Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
Netherton SJ; Maurice DH
Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
5. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
6. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
8. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
9. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
Suvarna NU; O'Donnell JM
J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
Sutor B; Mantell K; Bacher B
Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
[TBL] [Abstract][Full Text] [Related]
11. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.
Zhang KY; Card GL; Suzuki Y; Artis DR; Fong D; Gillette S; Hsieh D; Neiman J; West BL; Zhang C; Milburn MV; Kim SH; Schlessinger J; Bollag G
Mol Cell; 2004 Jul; 15(2):279-86. PubMed ID: 15260978
[TBL] [Abstract][Full Text] [Related]
12. Multiplicity within cyclic nucleotide phosphodiesterases.
Rybalkin SD; Beavo JA
Biochem Soc Trans; 1996 Nov; 24(4):1005-9. PubMed ID: 8968501
[No Abstract] [Full Text] [Related]
13. Dynamic regulation of cAMP signaling by cGMP in the cardiovascular system: roles of phosphodiesterase 2 and phosphodiesterase 3 enzymes.
Maurice DH
Proc West Pharmacol Soc; 2003; 46():32-6. PubMed ID: 14699879
[No Abstract] [Full Text] [Related]
14. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
15. Role of phosphodiesterase and protein kinase G on nitric oxide-induced inhibition of prolactin release from the rat anterior pituitary.
Velardez MO; De Laurentiis A; del Carmen Díaz M; Lasaga M; Pisera D; Seilicovich A; Duvilanski BH
Eur J Endocrinol; 2000 Aug; 143(2):279-84. PubMed ID: 10913949
[TBL] [Abstract][Full Text] [Related]
16. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
Qiu Y; Kraft P; Lombardi E; Clancy J
J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
[TBL] [Abstract][Full Text] [Related]
17. Differential susceptibility to biological detergents of the particulate cGMP-stimulated phosphodiesterase from rat heart: preservation of the allosteric properties of the solubilized enzyme.
Timouyasse L; Prigent AF; Némoz G; Lagarde M; Pachéco H
Biochem Int; 1989 Aug; 19(2):287-99. PubMed ID: 2554908
[TBL] [Abstract][Full Text] [Related]
18. Cyclic nucleotide phosphodiesterases in cultured normal and RCS rat pigment epithelium: kinetics of cyclic AMP and cyclic GMP hydrolysis.
Kurtz MJ; Edwards RB; Schmidt SY
Exp Eye Res; 1987 Jul; 45(1):67-75. PubMed ID: 2820772
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular implications in the use of PDE5 inhibitor therapy.
Maurice DH
Int J Impot Res; 2004 Jun; 16 Suppl 1():S20-3. PubMed ID: 15224131
[TBL] [Abstract][Full Text] [Related]
20. Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.
Zhao CY; Greenstein JL; Winslow RL
J Mol Cell Cardiol; 2015 Nov; 88():29-38. PubMed ID: 26388264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]